Better Therapeutics, Inc.: Nasdaq/NYSE listing notice — Better Therapeutics receives Nasdaq delisting notice; intends to appeal

Better Therapeutics, Inc.

Nasdaq notified Better Therapeutics on Dec 14, 2023 of delisting effective Dec 26, 2023 due to continued non-compliance with minimum bid price ($1.00) and MVLS ($35M) requirements.
Company had 180-day compliance period ending Dec 13, 2023 but failed to regain compliance; not eligible for additional extension.
Company intends to appeal to a Nasdaq Hearings Panel before Dec 21, 2023; appeal will stay delisting pending panel decision.
No assurance that appeal will succeed or that listing on Nasdaq Capital Market will be maintained.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Better Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5550(b)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5550(b)(2)

Exact text from the filing

continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires companies listed on the Nasdaq Capital Market to maintain a minimum bid price of at least $1 per share (the “Minimum Bid Price Requirement”). Nasdaq Listing Rule 5550(b)(2) requires companies listed on the Nasdaq Capital Market to maintain a minimum market value of listed

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-23-296870

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.